Accessibility StatementSkip Navigation - New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in an ESMO Presidential Symposium - TOKYO, Oct. 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present ten abstracts from our ...

ESSA filed supplemental proxy materials reflecting the previously announced revised terms of the Transaction on September 24, 2025 on the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Accessibility StatementSkip Navigation SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 30, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics In ...

Accessibility StatementSkip Navigation NEW YORK and PALO ALTO, Calif., Sept. 30, 2025 /PRNewswire/ --Â Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho" or "the Company") today announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. ("Turn"), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement, and customary closin ...

Accessibility StatementSkip Navigation - GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDAÂ IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - -Â Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - -Â BioLineRx affirms its cash runway into the first half of 2027 - Urgent Unmet Need and Significant Commercial Opportunity in Glioblastoma GBM is the most common a ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater. Evofem's ...

Accessibility StatementSkip Navigation DUBLIN, Ohio, Sept. 23, 2025 /PRNewswire/ -- Cardinal Health (NYSE:Â CAH) plans to release first-quarter financial results for its fiscal year 2026 on October 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides an ...

Multimodal Approach to Skin Quality at AMWC, Dubai Accessibility StatementSkip Navigation IRVINE, Calif., Sept. 23, 2025 /PRNewswire/ --  Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM in 35 additional markets this year bringing the total to 57 globally in 2025. This expansion underscores Allergan Aesthetics' global strategic commitment to enhancing skin quality worldwide. SKINVIVE is an advanced skincare solution for healthy-looking skin, delive ...

Accessibility StatementSkip Navigation BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to dete ...

Accessibility StatementSkip Navigation Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the ...

Accessibility StatementSkip Navigation NASDAQ | TSX: ACB About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniM ...